These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8658104)

  • 1. [Recent developments in antipsychotic medication].
    Möller HJ
    Schweiz Arch Neurol Psychiatr (1985); 1995; 146(5):230-9. PubMed ID: 8658104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology and treatment of negative symptoms.
    Villeneuve A
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia.
    Reynolds GP
    Acta Psychiatr Scand Suppl; 1994; 380():36-40. PubMed ID: 7914046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
    Keegan D
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
    Kerwin RW
    Br J Psychiatry; 1994 Feb; 164(2):141-8. PubMed ID: 7513599
    [No Abstract]   [Full Text] [Related]  

  • 9. Implications of brain imaging for the management of schizophrenia.
    Nyberg S; Nilsson U; Okubo Y; Halldin C; Farde L
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S15-20. PubMed ID: 9690965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current use of atypical antipsychotics.
    Müller-Spahn F
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():377s-384s. PubMed ID: 23573608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of risperidone.
    Ereshefsky L; Lacombe S
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S80-8. PubMed ID: 7504573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
    Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
    Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile of an atypical antipsychotic: risperidone.
    Davis JM; Chen N
    Schizophr Bull; 2002; 28(1):43-61. PubMed ID: 12047021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
    Nyberg S; Nakashima Y; Nordström AL; Halldin C; Farde L
    Br J Psychiatry Suppl; 1996 May; (29):40-4. PubMed ID: 8733822
    [No Abstract]   [Full Text] [Related]  

  • 17. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.
    de Haan L; Booij J; Lavalaye J; van Amelsvoort T; Linszen D
    Psychopharmacology (Berl); 2006 Jan; 183(4):500-5. PubMed ID: 16292589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does loxapine have "atypical" properties? Clinical evidence.
    Glazer WM
    J Clin Psychiatry; 1999; 60 Suppl 10():42-6. PubMed ID: 10340686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone: how good is the evidence for efficacy?
    Mattes JA
    Schizophr Bull; 1997; 23(1):155-61. PubMed ID: 9050121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.